1-4 of 4
Wally Smith, MD
Close
Save search
Sort by
Journal Articles

Tetrahydrobiopterin (6R-BH4): Novel Therapy for Endothelial Dysfunction in Sickle Cell Disease

Free
Lewis Hsu, MD, PhD, Kenneth I Ataga, M.D., Victor R. Gordeuk, MD, Paul S. Swerdlow, MD, Abdullah Kutlar, MD, Wally Smith, MD, J. Martin Johnston, MD, Ian A Chen, MD, MPH, FACP, Anne Greist, MD, Frances Flug, MD, Susumu Inoue, MD, Olise M. Nwose, MBBS, MRCPath, Saba Sile, MD, Emil Kakkis, MD, PhD
Journal: Blood
Blood (2008) 112 (11): lba-5.
https://doi.org/10.1182/blood.V112.11.lba-5.lba-5
Published: 2008
Journal Articles

Time Series Analysis of the Pain Diary Data Obtained during the Multicenter Study for Hydroxyurea (MSH) Clinical Trial.

Free
William F. McCarthy, PhD, Robert L. Bauserman, PhD, Bruce A. Barton, PhD, Nan Guo, BS, Samir K. Ballas, MD, Wally Smith, MD
Journal: Blood
Blood (2006) 108 (11): 3807.
https://doi.org/10.1182/blood.V108.11.3807.3807
Published: 2006
Journal Articles

A 48-Week Open-Label Study of Senicapoc (ICA-17043), a Gardos Channel Blocker, in Patients with Sickle Cell Disease.

Free
Paul Swerdlow, MD, Kenneth Ataga, MD, Wally Smith, MD, Yogen Saunthararajah, MD, Jonathan W. Stocker, PhD
Journal: Blood
Blood (2006) 108 (11): 685.
https://doi.org/10.1182/blood.V108.11.685.685
Published: 2006
Journal Articles

Efficacy and Safety of the Gardos Channel Inhibitor, ICA-17043, in Patients with Sickle Cell Anemia.

Free
Kenneth I. Ataga, MBBS, Laura M. DeCastro, MD, Paul Swerdlow, MD, Yogen Saunthararajah, MD, Wally Smith, MD, The ICA-17043 Study Investigators6
Journal: Blood
Blood (2004) 104 (11): 103.
https://doi.org/10.1182/blood.V104.11.103.103
Published: 2004